1. Show article details.

    BRIEF-Bluebird Bio And Resilience Announce Alliance

    Reuters – 8:09 AM ET 07/28/2021

    Bluebird bio Inc (BLUE): * BLUEBIRD BIO AND RESILIENCE ANNOUNCE STRATEGIC ALLIANCE TO DEVELOP NEXT GENERATION CELL THERAPIES. * BLUEBIRD BIO (BLUE) - TO RECEIVE $110 MILLION UPFRONT, PREFERRED LVV MANUFACTURING ACCESS AND SIGNIFICANTLY REDUCE OPERATIONAL EXPENSES OVER COMING YEARS.

  2. Show article details.

    Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

    Business Wire – 8:00 AM ET 07/28/2021

    Resilience to acquire bluebird’s clinical and commercial suspension lentiviral vector manufacturing facility in North Carolina, retaining all current employees at the site Alliance designed to foster best in class cell therapy product and manufacturing innovation through risk-sharing and royalty-based model bluebird to receive $110M upfront, preferred LVV manufacturing access and significantl...

  3. Show article details.

    Bristol Myers Squibb Reports Second Quarter Financial Results for 2021

    Business Wire – 6:59 AM ET 07/28/2021

    NEW YORK---- Bristol Myers Squibb (BMY) today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company.

  4. Show article details.

    BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

    PR Newswire – 10:50 PM ET 07/23/2021

    NEW ORLEANS, La., July 23, 2021 Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into bluebird bio, Inc..  . In May 2020, the Company announced its plans to submit an application to the U.S. Food and Drug Administration for its product, LentiGlobin, in the second half of 2021.

  5. Show article details.

    BRIEF-Bluebird Bio Receives European Commission Approval For Skysona Gene Therapy

    Reuters – 5:05 AM ET 07/21/2021

    bluebird bio Inc: * BLUEBIRD BIO RECEIVES EC APPROVAL FOR SKYSONA™ GENE THERAPY FOR PATIENTS LESS THAN 18 YEARS OF AGE WITH EARLY CEREBRAL ADRENOLEUKODYSTROPHY WITHOUT MATCHED SIBLING DONOR. * SKYSONA IS THE FIRST AND ONLY GENE THERAPY APPROVED IN THE EU TO TREAT EARLY CALD Source text for Eikon: Further company coverage:

  6. Show article details.

    bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

    Business Wire – 5:00 AM ET 07/21/2021

    SKYSONA is the first and only gene therapy approved in the EU to treat early CALD CALD is a rare neurodegenerative disease that can lead to progressive, irreversible loss of neurologic function, and death One-time treatment with SKYSONA has been shown to have a durable effect in improving survival outcomes and preserving neurologic function across pivotal and long-term studies, with the longes...

  7. Show article details.

    BRIEF-Bluebird Bio Announces Positive Recommendation By Prac Regarding Article 20 Safety Referral Review Of Zynteglo™ Gene Therapy

    Reuters – 11:32 AM ET 07/09/2021

    BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO ANNOUNCES POSITIVE RECOMMENDATION BY PRAC REGARDING ARTICLE 20 SAFETY REFERRAL REVIEW OF ZYNTEGLO™ GENE THERAPY FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA AND MARKETING TO RESUME IN EU. * BLUEBIRD BIO INC (BLUE) - COMPANY HAS INFORMED EMA OF LIFT OF VOLUNTARY TEMPORARY MARKETING SUSPENSION.

  8. Show article details.

    bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU

    Business Wire – 7:30 AM ET 07/09/2021

    EMA’s Pharmacovigilance Risk Assessment Committee confirms favorable benefit-risk balance of ZYNTEGLO Company has informed EMA of lift of voluntary temporary marketing suspension bluebird bio, Inc. today announced that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee has concluded based on the review of all available data that the benefit-risk balance of medicinal p...

  9. Show article details.

    BRIEF-EMA Finds No Evidence Linking Viral Vector In Zynteglo To Blood Cancer

    Reuters – 7:14 AM ET 07/09/2021

    * EMA: EMA FINDS NO EVIDENCE LINKING VIRAL VECTOR IN ZYNTEGLO TO BLOOD CANCER: Further company coverage:

  10. Show article details.

    BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

    Business Wire – 10:50 PM ET 06/11/2021

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into bluebird bio, Inc.. In May 2020, the Company announced its plans to submit an application to the U.S. Food and Drug Administration for its product, LentiGlobin, in the second half of 2021.

  11. Show article details.

    betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual

    Business Wire – 5:00 AM ET 06/11/2021

    With 51 patients enrolled, data from the long-term follow-up study show that all patients treated with beti-cel who achieve transfusion independence remain free from transfusions, with the longest follow-up of seven years Across Phase 3 studies, 89% of evaluable patients across ages and genotypes achieved TI and remain transfusion free, including 91% of evaluable pediatric patients under the a...

  12. Show article details.

    bluebird bio to Present at Goldman Sachs Global Healthcare Conference

    Business Wire – 4:05 PM ET 06/07/2021

    bluebird bio, Inc. today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET.

  13. Show article details.

    BRIEF-Bluebird Bio Announces Lifting Of FDA Clinical Hold For Sickle Cell Disease And Β-Thalassemia Studies

    Reuters – 8:54 AM ET 06/07/2021

    BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO ANNOUNCES LIFTING OF FDA CLINICAL HOLD FOR SICKLE CELL DISEASE AND Β-THALASSEMIA STUDIES. * BLUEBIRD BIO INC (BLUE) - IS WORKING CLOSELY WITH STUDY INVESTIGATORS AND CLINICAL TRIAL SITES TO RESUME ALL STUDY ACTIVITIES AS SOON AS POSSIBLE Source text for Eikon: Further company coverage:

  14. Show article details.

    bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies

    Business Wire – 8:00 AM ET 06/07/2021

    bluebird bio, Inc. today announced that the U.S. Food and Drug Administration has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease gene therapy for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 and Northstar-3 studies of betibeglogene autotemcel gene therapy for adult, adolescent and pediatric patients wit...

  15. Show article details.

    bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)

    Business Wire – 4:05 PM ET 06/02/2021

    bluebird bio, Inc. today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 50,000 shares of common stock and 25,000 restricted stock units to its Chief Commercial Officer Tom Klima with a grant date of June 1, 2021.

  16. Show article details.

    BRIEF-bluebird bio Receives Positive CHMP Opinion For Skysona Gene Therapy For Patients With Early Cerebral Adrenoleukodystrophy

    Reuters – 8:06 AM ET 05/21/2021

    BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO RECEIVES POSITIVE CHMP OPINION FOR SKYSONA GENE THERAPY FOR PATIENTS LESS THAN 18 YEARS OF AGE WITH EARLY CEREBRAL ADRENOLEUKODYSTROPHY. * BLUEBIRD BIO INC (BLUE) - AS OF DATA CUTOFF DATE, 90% PATIENTS TREATED WITH SKYSONA IN PIVOTAL ALD-102 CLINICAL STUDY MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

  17. Show article details.

    bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)

    Business Wire – 8:00 AM ET 05/21/2021

    SKYSONA is the first and only gene therapy recommended for approval for patients with CALD, a progressive, neurodegenerative disease As of the data cutoff date, 90% of patients treated with SKYSONA in the pivotal ALD-102 clinical study met the primary endpoint of major functional disability-free survival at two years of follow-up Data from the long-term follow-up study suggest that SKYSONA co...

  18. Show article details.

    BRIEF-Bristol Myers Says Data From Pivotal Karmma Study Show 24.8-Month Median Overall Survival In Triple-Class Exposed Multiple Myeloma

    Reuters – 6:03 PM ET 05/19/2021

    BRISTOL MYERS: * DATA FROM PIVOTAL KARMMA STUDY SHOW 24.8-MONTH MEDIAN OVERALL SURVIVAL IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA. * CYTOPENIAS, CYTOKINE RELEASE SYNDROME WERE MOST COMMON ADVERSE EVENTS OF ANY GRADE IN KARMMA STUDY. * INVESTIGATOR-REPORTED NEUROTOXICITY OF ANY GRADE WAS REPORTED IN 18% OF PATIENTS IN KARMMA STUDY.

  19. Show article details.

    Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma

    Business Wire – 5:00 PM ET 05/19/2021

    Data from pivotal KarMMa study to be presented at ASCO21 show 24.8-month median overall survival in triple-class exposed multiple myeloma With more than 24-month median follow-up, results represent longest follow-up to date from a global clinical trial of a CAR T cell therapy in multiple myeloma with 73% overall response rate and responses ongoing Analysis of characteristics of neurotoxicity ob...

  20. Show article details.

    AavantiBio Rounds Out Leadership Team with Appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer

    Business Wire – 7:00 AM ET 05/17/2021

    AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer. Dr. Hanrahan brings to AavantiBio nearly 15 years of experience in the biotech industry and a strong track record of achievements and leadership in global regulatory affairs and drug development.

Page:

Today's and Upcoming Events

  • Aug
    03

    BLUE to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    05

    BLUE announced Q1 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.